Europe
It would be used to fill in the gaps seen in funding for vaccines, treatments and diagnostic testing.
While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.
Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
Keele, UK, 31 March 2020: Cobra Biologics, an international CDMO for biologics and pharmaceuticals, announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19, for fast-tracked clinical trials for COVID-19.
The study reveals that brain tumors in babies are molecularly unique and could be candidates for targeted treatments.
During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer’s disease.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
SARS was called the first pandemic of the 21st century. It would not be the last. Nor would it be the most deadly.
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
PRESS RELEASES